IP Library › Granted Patent US 10,286,027
Granted Patent B2
US 10,286,027 · App. 14/800,950 · Granted May 14, 2019

Sustained release formulations of curcuminoids and method of preparation thereof

Inventor: Benny Antony (Ankamaly, IN)
Assignee: ARJUNA NATURAL EXTRACTS, LTD.
A61K36/9066A61K9/0053A61K31/12A61K47/32A61K47/38A61K47/44
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,286,027
App. No.
14/800,950
Granted
May 14, 2019
Kind
B2
Abstract

A sustained release curcuminoid composition having a bioavailable curcumin composition and a release rate controlling excipient. The bioavailable composition of curcumin includes a curcuminoid mixture and an added essential oil of turmeric. The curcuminoid mixture includes curcumin, demethoxycurcumin and bisdemethoxycurcumin. The added essential oil of turmeric includes about 40% to about 50% of ar-turmerone. Methods of preparing sustained release compositions having a bioavailable curcumin composition and a release rate controlling excipient.

Claims (32)

1. A sustained release curcuminoid composition comprising a bioavailable curcumin composition and a release rate controlling excipient, wherein the bioavailable composition of curcumin comprises a curcuminoid mixture and an added essential oil of turmeric, the curcuminoid mixture comprises curcumin, demethoxycurcumin and bisdemethoxycurcumin, and, the added essential oil of turmeric comprises about 40% to about 50% of ar-turmerone, wherein the release rate controlling excipient is selected from the group consisting of ethyl cellulose, shellac, copolymer of ethyl acrylate and methyl methacrylate, and combinations thereof.

2. The sustained release curcuminoid composition of claim 1 , wherein the added essential oil of turmeric comprises about 45% ar-turmerone.

3. The sustained release curcuminoid composition of claim 1 , wherein a weight ratio of the curcuminoid mixture to the added essential oil of turmeric ranges from about 1:3 to about 99:1.

4. The sustained release curcuminoid composition of claim 1 , wherein the weight ratio of the curcuminoid mixture to the added essential oil of turmeric is about 10:1.

5. The sustained release curcuminoid composition of claim 1 , wherein the weight ratio of the curcuminoid mixture to the added essential oil of turmeric is about 12:1.

6. The sustained release curcuminoid composition of claim 1 , wherein a weight ratio of the bioavailable curcumin composition to the release rate controlling excipient ranges from about 3:1 to about 50:1.

7. The sustained release curcuminoid composition of claim 1 , wherein a weight ratio of the bioavailable curcumin composition to the release rate controlling excipient ranges from about 10:1 to about 20:1.

8. The sustained release curcuminoid composition of claim 1 , wherein a weight ratio of the bioavailable curcumin composition to the release rate controlling excipient is about 10:1.

9. The sustained release curcuminoid composition of claim 1 , wherein a weight ratio of the bioavailable curcumin composition to the release rate controlling excipient is about 14:1.

10. The sustained release curcuminoid composition of claim 1 , wherein a weight ratio of the bioavailable curcumin composition to the release rate controlling excipient is about 20:1.

11. The sustained release curcuminoid composition of claim 1 , wherein a weight ratio of the bioavailable curcumin composition to the shellac ranges from about 3:1 to about 50:1.

12. The sustained release curcuminoid composition of claim 1 , wherein the weight ratio of the bioavailable curcumin composition to the shellac ranges from about 10:1 to about 14:1.

13. The sustained release curcuminoid composition of claim 1 , wherein a weight ratio of the bioavailable curcumin composition to the shellac is about 10:1.

14. The sustained release curcuminoid composition of claim 1 , wherein a weight ratio of the bioavailable curcumin composition to the shellac is about 14:1.

15. The sustained release curcuminoid composition of claim 1 , wherein the shellac forms a coating on the bioavailable curcumin composition.

16. The sustained release curcuminoid composition of claim 1 , wherein a weight ratio of the bioavailable curcumin composition to the ethyl cellulose ranges from about 3:1 to about 50:1.

17. The sustained release curcuminoid composition of claim 1 , wherein the weight ratio of the e bioavailable curcumin composition to the ethyl cellulose ranges from about 10:1 to about 20:1.

18. The sustained release curcuminoid composition of claim 1 , wherein a weight ratio of the bioavailable curcumin composition to the ethyl cellulose is about 10:1.

19. The sustained release curcuminoid composition of claim 1 , wherein a weight ratio of the bioavailable curcumin composition to the ethyl cellulose is about 20:1.

20. The sustained release curcuminoid composition of claim 1 , wherein the ethyl cellulose forms a coating on the bioavailable curcumin composition.

21. The sustained release curcuminoid composition of claim 1 , wherein a weight ratio of the bioavailable curcumin composition to the copolymer of ethyl acrylate and methyl methacrylate ranges from about 3:1 to about 50:1.

22. The sustained release curcuminoid composition of claim 1 , wherein the weight ratio of the bioavailable curcumin composition to the copolymer of ethyl acrylate and methyl methacrylate ranges from about 10:1 to about 20:1.

23. The sustained release curcuminoid composition of claim 1 for oral administration.

24. The sustained release curcuminoid composition of claim 1 , wherein curcumin, demethoxycurcumin and bisdemethoxycurcumin are detected in the blood for about 24 to about 36 hours.

25. The sustained release curcuminoid composition of claim 1 , wherein a single dosage of the composition provides curcumin, demethoxycurcumin and bisdemethoxycurcumin in the body for 24 hours.

26. The sustained release curcuminoid composition of claim 1 , wherein a single dosage of the composition provides curcumin, demethoxycurcumin and bisdemethoxycurcumin in the body for 36 hours.

27. The sustained release curcuminoid composition of claim 1 , wherein administering a single dosage of the sustained release curcuminoid composition enhances bioavailability of curcumin, demethoxycurcumin and bisdemethoxycurcumin in the blood for 24 hours when compared to administration of the bioavailable curcumin composition alone.

28. The sustained release curcuminoid composition of claim 1 , wherein administering a single dosage of the sustained release curcuminoid composition enhances bioavailability of curcumin, demethoxycurcumin and bisdemethoxycurcumin in the blood for 36 hours when compared to administration of the bioavailable curcumin composition alone.

29. The sustained release curcuminoid composition of claim 1 , wherein administering a single dosage of the sustained release curcuminoid composition enhances bioavailability of curcumin, demethoxycurcumin and bisdemethoxycurcumin in a body tissue for more than 24 hours when compared to administration of the bioavailable curcumin composition alone.

30. The sustained release curcuminoid composition of claim 1 , wherein the half-life (t 1/2 ) of the curcumin, demethoxycurcumin and bisdemethoxycurcumin in the blood is increased when compared to the half life (t 1/2 ) of curcumin, demethoxycurcumin and bisdemethoxycurcumin in the blood upon administration of the bioavailable curcumin composition alone.

31. The sustained release curcuminoid composition of claim 1 , wherein the area under the curve (AUC) of the curcumin, demethoxycurcumin and bisdemethoxycurcumin in the blood is increased when compared to the AUC of curcumin, demethoxycurcumin and bisdemethoxycurcumin upon administration of the bioavailable curcumin composition alone.

32. A dosage form comprising the sustained release curcuminoid composition of claim 1 , wherein the dosage form is selected from the group consisting of powder, pellets, granules, tablets and capsules.

Assignments (1)
NUNC PRO TUNC ASSIGNMENT Recorded Nov 28, 2018
From: ANTONY, BENNY
To: ARJUNA NATURAL EXTRACTS, LTD.
Reel/Frame 047612/0763 →
Priority Claims (3)
IN 950/CHE/2010 · Apr 5, 2010 · national
IN 4128/CHE/2012 · Nov 3, 2012 · national
IN 226/CHE/2013 · Jan 17, 2013 · national
Continuity (27)
Continuation In Part 14476555 · Sep 3, 2014
Division 13645031 · Oct 4, 2012
Division 14800950
Continuation In Part 14623608 · Feb 17, 2015
Continuation In Part 14520292 · Oct 21, 2014
Continuation In Part 14206044 · Mar 12, 2014
Continuation In Part PCTIN2011000232 · Apr 4, 2011
Division 13674249 · Nov 12, 2012
Division 13506572 · Apr 30, 2012
Division 12926980 · Dec 21, 2010
Division 12073864 · Mar 11, 2008
Continuation In Part 11635599 · Dec 8, 2006
Division 14094725 · Dec 2, 2013
Division 13385717 · Mar 5, 2012
Division 12926985 · Dec 21, 2010
Division 12662740 · Apr 30, 2010
Division 11635599 · Dec 8, 2006
Continuation PCTIN2005000176 · May 30, 2005
Continuation In Part 13645031 · Oct 4, 2012
Continuation In Part 13674249 · Nov 12, 2012
Continuation In Part 14094725 · Dec 2, 2013
Continuation In Part 14800950
Continuation PCTIN2014000031 · Jan 16, 2014
Continuation In Part 14698944 · Apr 29, 2015
Continuation PCTIN2013000673 · Oct 31, 2013
Provisional Application 61794175 · Mar 15, 2013
Related Publication 20160067300A1 · Mar 10, 2016
Cited By (1)
US 12,251,415